Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd ... MarketWatch (press release) (13,14) Inotuzumab is currently being evaluated in a Phase 3 study in combination with rituximab in patients with relapsed or refractory CD22-positive aggressive NHL who are not candidates for intensive high-dose chemotherapy.(7) For the first time, ... |
